• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全身磁共振成像评估小鼠尤文肉瘤的扩散和 T 细胞治疗反应。

Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.

机构信息

Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany.

出版信息

Br J Cancer. 2013 Aug 6;109(3):658-66. doi: 10.1038/bjc.2013.356. Epub 2013 Jul 9.

DOI:10.1038/bjc.2013.356
PMID:23839490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3738111/
Abstract

BACKGROUND

Novel treatment strategies in Ewing sarcoma include targeted cellular therapies. Preclinical in vivo models are needed that reflect their activity against systemic (micro)metastatic disease.

METHODS

Whole-body magnetic resonance imaging (WB-MRI) was used to monitor the engraftment and dissemination of human Ewing sarcoma xenografts in mice. In this model, we evaluated the therapeutic efficacy of T cells redirected against the Ewing sarcoma-associated antigen GD2 by chimeric receptor engineering.

RESULTS

Of 18 mice receiving intravenous injections of VH-64 Ewing sarcoma cells, all developed disseminated tumour growth detectable by WB-MRI. All mice had lung tumours, and the majority had additional manifestations in the bone, soft tissues, and/or kidney. Sequential scans revealed in vivo growth of tumours. Diffusion-weighted whole-body imaging with background signal suppression effectively visualised Ewing sarcoma growth in extrapulmonary sites. Animals receiving GD2-targeted T-cell therapy had lower numbers of pulmonary tumours than controls, and the median volume of soft tissue tumours at first detection was lower, with a tumour growth delay over time.

CONCLUSION

Magnetic resonance imaging reliably visualises disseminated Ewing sarcoma growth in mice. GD2-retargeted T cells can noticeably delay tumour growth and reduce pulmonary Ewing sarcoma manifestations in this aggressive disease model.

摘要

背景

尤文肉瘤的新型治疗策略包括靶向细胞疗法。需要能够反映其针对系统性(微)转移性疾病活性的临床前体内模型。

方法

全身磁共振成像(WB-MRI)用于监测人尤文肉瘤异种移植物在小鼠中的植入和扩散。在该模型中,我们通过嵌合受体工程评估了针对尤文肉瘤相关抗原 GD2 的 T 细胞的治疗效果。

结果

18 只接受静脉注射 VH-64 尤文肉瘤细胞的小鼠均发生了可通过 WB-MRI 检测到的弥散性肿瘤生长。所有小鼠均有肺部肿瘤,大多数小鼠还有骨、软组织和/或肾脏的其他表现。连续扫描显示体内肿瘤生长。背景信号抑制的全身扩散加权成像有效地可视化了肺外部位尤文肉瘤的生长。接受 GD2 靶向 T 细胞治疗的动物比对照组的肺部肿瘤数量更少,首次检测到的软组织肿瘤体积更低,并且随着时间的推移肿瘤生长延迟。

结论

磁共振成像可可靠地可视化小鼠中播散性尤文肉瘤的生长。GD2 重定向 T 细胞可明显延迟肿瘤生长,并减少该侵袭性疾病模型中的肺部尤文肉瘤表现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/aeceb1ef688e/bjc2013356f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/4b4d44daa6bb/bjc2013356f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/f81a92d09695/bjc2013356f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/f554f0b6e284/bjc2013356f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/aeceb1ef688e/bjc2013356f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/4b4d44daa6bb/bjc2013356f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/f81a92d09695/bjc2013356f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/f554f0b6e284/bjc2013356f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398b/3738111/aeceb1ef688e/bjc2013356f4.jpg

相似文献

1
Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.全身磁共振成像评估小鼠尤文肉瘤的扩散和 T 细胞治疗反应。
Br J Cancer. 2013 Aug 6;109(3):658-66. doi: 10.1038/bjc.2013.356. Epub 2013 Jul 9.
2
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.神经节苷脂抗原 G(D2)在尤文肉瘤中表面表达,允许 MHC 非依赖性免疫靶向。
Br J Cancer. 2012 Mar 13;106(6):1123-33. doi: 10.1038/bjc.2012.57. Epub 2012 Feb 28.
3
EZH2 Inhibition in Ewing Sarcoma Upregulates G Expression for Targeting with Gene-Modified T Cells.EZH2 抑制在尤文肉瘤中上调 G 表达,用于基因修饰 T 细胞的靶向治疗。
Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23.
4
Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.应用先进的活体成像技术开发尤文肉瘤和其他人类恶性骨疾病的临床前原位异种移植模型。
PLoS One. 2014 Jan 7;9(1):e85128. doi: 10.1371/journal.pone.0085128. eCollection 2014.
5
VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma.VEGFR2 作为嵌合抗原受体 T 细胞治疗尤文肉瘤的靶点。
Pediatr Blood Cancer. 2020 Oct;67(10):e28313. doi: 10.1002/pbc.28313. Epub 2020 Jul 30.
6
GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.GD2 导向的 CAR-T 细胞与 HGF 靶向中和抗体(AMG102)联合应用可预防尤文肉瘤的原发肿瘤生长和转移。
Int J Cancer. 2020 Jun 1;146(11):3184-3195. doi: 10.1002/ijc.32743. Epub 2019 Nov 6.
7
A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma.用于尤文肉瘤免疫治疗临床前评估的人源化原位小鼠模型。
Front Immunol. 2023 Oct 6;14:1277987. doi: 10.3389/fimmu.2023.1277987. eCollection 2023.
8
Indoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcoma.尤因肉瘤免疫治疗模型中的吲哚胺-2,3-双加氧酶
Anticancer Res. 2014 Nov;34(11):6431-41.
9
Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.功能、化学基因组学和超级增强子筛选确定尤因肉瘤对细胞周期蛋白D1/细胞周期蛋白依赖性激酶4通路抑制的敏感性。
Oncotarget. 2015 Oct 6;6(30):30178-93. doi: 10.18632/oncotarget.4903.
10
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.全反式维甲酸减少骨髓来源抑制细胞可提高肉瘤嵌合抗原受体治疗效果。
Cancer Immunol Res. 2016 Oct;4(10):869-880. doi: 10.1158/2326-6066.CIR-15-0230. Epub 2016 Aug 22.

引用本文的文献

1
LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma.LOXHD1是尤因肉瘤的一种癌融合调节抗原。
Sci Rep. 2025 Apr 15;15(1):13007. doi: 10.1038/s41598-025-96877-9.
2
The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence.嵌合抗原受体(CAR)T细胞疗法用于原发性骨肿瘤的疗效及适用性:当前证据的全面综述
J Bone Oncol. 2024 Sep 22;48:100635. doi: 10.1016/j.jbo.2024.100635. eCollection 2024 Oct.
3
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.

本文引用的文献

1
The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease.尤因肉瘤中的CXCR4-CXCL12轴:促进肿瘤生长而非转移性疾病。
Clin Sarcoma Res. 2012 Dec 18;2(1):24. doi: 10.1186/2045-3329-2-24.
2
Detecting peritoneal dissemination of ovarian cancer in mice by DWIBS.通过 DWIBS 检测小鼠卵巢癌的腹膜播散。
Magn Reson Imaging. 2013 Feb;31(2):227-34. doi: 10.1016/j.mri.2012.06.016. Epub 2012 Aug 24.
3
EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.
嵌合抗原受体 T 细胞作为针对实体瘤的微型药物工厂:在一步工程化过程中将效应 T 细胞介导的细胞死亡与血管靶向相结合。
Cancer Gene Ther. 2023 Oct;30(10):1355-1368. doi: 10.1038/s41417-023-00642-x. Epub 2023 Jun 30.
4
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness.软组织和骨肉瘤的免疫治疗:揭开疗效的障碍。
Theranostics. 2022 Aug 15;12(14):6106-6129. doi: 10.7150/thno.72800. eCollection 2022.
5
Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma.抗GD2嵌合抗原受体间充质干细胞治疗转移性尤因肉瘤
Transl Oncol. 2022 Jan;15(1):101240. doi: 10.1016/j.tranon.2021.101240. Epub 2021 Oct 12.
6
A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.一种新的尤文肉瘤治疗方法:嵌合抗原受体 T 细胞疗法。
Front Immunol. 2021 Sep 10;12:707211. doi: 10.3389/fimmu.2021.707211. eCollection 2021.
7
HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells.HLA-G和HLA-E免疫检查点在尤因肉瘤中广泛表达,但对抗抗原特异性嵌合抗原受体T细胞(CAR T细胞)的效应功能影响有限。
Cancers (Basel). 2021 Jun 8;13(12):2857. doi: 10.3390/cancers13122857.
8
Longitudinal imaging of T cell-based immunotherapy with multi-spectral, multi-scale optoacoustic tomography.基于多光谱、多尺度光声断层成像的 T 细胞免疫治疗的纵向成像。
Sci Rep. 2020 Mar 17;10(1):4903. doi: 10.1038/s41598-020-61191-z.
9
Bridging the translational gap: Implementation of multimodal small animal imaging strategies for tumor burden assessment in a co-clinical trial.弥合转化差距:联合临床试验中多模态小动物成像策略在肿瘤负担评估中的应用。
PLoS One. 2019 Apr 8;14(4):e0207555. doi: 10.1371/journal.pone.0207555. eCollection 2019.
10
EZH2 Inhibition in Ewing Sarcoma Upregulates G Expression for Targeting with Gene-Modified T Cells.EZH2 抑制在尤文肉瘤中上调 G 表达,用于基因修饰 T 细胞的靶向治疗。
Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23.
EWS-FLI-1 靶向细胞毒性 T 细胞杀伤属于尤文肉瘤家族肿瘤的多种肿瘤类型。
Clin Cancer Res. 2012 Oct 1;18(19):5341-51. doi: 10.1158/1078-0432.CCR-12-1985. Epub 2012 Aug 9.
4
Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.非小细胞肺癌的术前分期:全身扩散加权磁共振成像与 18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的比较。
Eur Radiol. 2012 Dec;22(12):2859-67. doi: 10.1007/s00330-012-2542-y. Epub 2012 Jul 9.
5
The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.神经节苷脂抗原 G(D2)在尤文肉瘤中表面表达,允许 MHC 非依赖性免疫靶向。
Br J Cancer. 2012 Mar 13;106(6):1123-33. doi: 10.1038/bjc.2012.57. Epub 2012 Feb 28.
6
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.嵌合抗原受体修饰 T 细胞抗 CD19 治疗的临床试验中,B 细胞耗竭和恶性肿瘤缓解,以及细胞因子相关毒性。
Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.
7
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.抗胰岛素样生长因子 1 型受体抗体 figitumumab 治疗难治性尤文肉瘤患者的初步疗效。
J Clin Oncol. 2011 Dec 1;29(34):4534-40. doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24.
8
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.嵌合抗原受体阳性 T 细胞治疗神经母细胞瘤的抗肿瘤活性和长期转归。
Blood. 2011 Dec 1;118(23):6050-6. doi: 10.1182/blood-2011-05-354449. Epub 2011 Oct 7.
9
Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT.全身 MRI 弥散加权成像联合三维对比增强 T1 加权成像在肿瘤分期中的作用:与 PET-CT 的比较。
Eur J Radiol. 2012 Aug;81(8):1917-25. doi: 10.1016/j.ejrad.2011.08.005. Epub 2011 Sep 9.
10
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.自体 CD19 靶向 T 细胞过继转移治疗复发或化疗耐药 B 细胞白血病患者的安全性和持久性。
Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.